哈药集团生物疫苗有限公司邬立权：锚定生物经济新赛道 助力东北亚创新高地建设

Core Insights - The event themed "Creating a New Engine for the Development of the Biological Economy in Heilongjiang" highlighted the achievements of Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. (referred to as "Harbin Vaccine") as a leading enterprise in veterinary biological products in Heilongjiang for 63 years, showcasing the synergy of resource endowment, technological reserves, and policy support in the region's biological economy [2] Group 1 - Harbin Vaccine has established a solid innovation foundation through its SPF experimental animal production base and deep collaborations with various research institutions, leading to significant growth in recent years [2] - The company has received 10 new veterinary drug certificates and generated nearly 10 million yuan in technology transfer income, with new product sales exceeding 20 million yuan, covering over 80% of the national market [2] Group 2 - Three key recommendations were proposed to address industry pain points: forming a provincial innovation consortium for veterinary biological products to integrate resources from universities, research institutions, and leading enterprises; establishing a risk warning mechanism for the supply chain; and creating a local supply-demand matching platform to promote the application of local vaccine products in large-scale breeding enterprises [3]